In CANTOS, they met their primary endpoint (3-point MACE) with statistical significance. 3-point MACE events were reduced by 14-15%. Most of the effect was due to a significant reduction in myocardial infarction with no significant differences in occurrence of cardiovascular death or stroke. This is somewhat similar to the results of the anti-PCSK9 antibody evolocumab FOURIER trial results announced in the spring in which non-fatal stroke and MI were reduced but not cardiovascular death. Both FOURIER and CANTOS are clinically significant in my opinion. FOURIER validates the LDL hypothesis and CANTOS validates the inflammation hypothesis for reducing cardiovascular risk. What FOURIER and CANTOS also have in common are that they are expensive antibody therapies that are cost prohibitive for widespread standard of care use unless their price comes down. The failure of PCSK9 and IL-1beta antibody therapies won't be statistically or clinically significant effects, but instead their downfall will be too costly of a therapy for widespread use.